Thomas J Spencer

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter
    Thomas J Spencer
    Pediatric Psychopharmacology Unit, Psychiatry Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Psychiatry 57:1293-300. 2005
  2. ncbi Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD?
    Thomas J Spencer
    Massachusetts General Hospital, Boston, 02114, USA
    J Am Acad Child Adolesc Psychiatry 45:527-37. 2006
  3. ncbi Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity
    Thomas J Spencer
    Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, Boston, USA
    J Clin Psychiatry 67:415-20. 2006
  4. ncbi PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate
    Thomas J Spencer
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Am J Psychiatry 163:387-95. 2006
  5. ncbi Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study
    Thomas J Spencer
    Department of Psychiatry, Massachusetts General Hospital, Pediatric Psychopharmacology Research Unit, 55 Fruit St, Warren 705, Boston, MA 02114, USA
    J Clin Psychiatry 69:1437-48. 2008
  6. ncbi Validation of the adult ADHD investigator symptom rating scale (AISRS)
    Thomas J Spencer
    Massachusetts General Hospital, Boston, MA 02114, USA
    J Atten Disord 14:57-68. 2010
  7. ncbi Attention-deficit/hyperactivity disorder-specific quality of life with triple-bead mixed amphetamine salts (SPD465) in adults: results of a randomized, double-blind, placebo-controlled study
    Thomas J Spencer
    Massachusetts General Hospital, Pediatric Psychopharmacology Research Unit, 55 Fruit St, Warren 705, Boston, MA 02114, USA
    J Clin Psychiatry 69:1766-75. 2008
  8. ncbi Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder
    Thomas J Spencer
    Pediatric Psychopharmacology Research Clinic, Massachusetts General Hospital, Boston, Massachusetts 02114, and New York University School of Medicine, New York, NY, USA
    Biol Psychiatry 61:1380-7. 2007
  9. ncbi Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment
    Thomas J Spencer
    Massachusetts General Hospital Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    J Child Adolesc Psychopharmacol 17:689-700. 2007
  10. ncbi An open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension
    Timothy E Wilens
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston 02114, USA
    J Clin Psychiatry 67:696-702. 2006

Research Grants

  1. CONTROLLED STUDY OF METHYLPHENIDATE IN ADULTS WITH ADHD
    Thomas Spencer; Fiscal Year: 2002
  2. Dopamine Transporter Binding by PET in Adult ADHD
    Thomas Spencer; Fiscal Year: 2007

Detail Information

Publications87

  1. ncbi In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter
    Thomas J Spencer
    Pediatric Psychopharmacology Unit, Psychiatry Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Psychiatry 57:1293-300. 2005
    ..Interpretation of the latter finding awaits clarification of the issue of timing of drug administration and imaging to disentangle receptor occupancy from downregulation...
  2. ncbi Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD?
    Thomas J Spencer
    Massachusetts General Hospital, Boston, 02114, USA
    J Am Acad Child Adolesc Psychiatry 45:527-37. 2006
    ..To investigate whether prolonged therapy with a long-acting stimulant affects growth in children with attention-deficit/hyperactivity disorder (ADHD)...
  3. ncbi Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity
    Thomas J Spencer
    Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, Boston, USA
    J Clin Psychiatry 67:415-20. 2006
    ....
  4. ncbi PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate
    Thomas J Spencer
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Am J Psychiatry 163:387-95. 2006
    ....
  5. ncbi Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study
    Thomas J Spencer
    Department of Psychiatry, Massachusetts General Hospital, Pediatric Psychopharmacology Research Unit, 55 Fruit St, Warren 705, Boston, MA 02114, USA
    J Clin Psychiatry 69:1437-48. 2008
    ....
  6. ncbi Validation of the adult ADHD investigator symptom rating scale (AISRS)
    Thomas J Spencer
    Massachusetts General Hospital, Boston, MA 02114, USA
    J Atten Disord 14:57-68. 2010
    ..Validation of the Adult ADHD Investigator Symptom Rating Scale (AISRS) that measures aspects of ADHD in adults...
  7. ncbi Attention-deficit/hyperactivity disorder-specific quality of life with triple-bead mixed amphetamine salts (SPD465) in adults: results of a randomized, double-blind, placebo-controlled study
    Thomas J Spencer
    Massachusetts General Hospital, Pediatric Psychopharmacology Research Unit, 55 Fruit St, Warren 705, Boston, MA 02114, USA
    J Clin Psychiatry 69:1766-75. 2008
    ..To assess the quality of life (QOL) in adults with attention-deficit/hyperactivity disorder (ADHD) given triple-bead mixed amphetamine salts (MAS), a long-acting amphetamine formulation designed for a duration of action of up to 16 hours...
  8. ncbi Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder
    Thomas J Spencer
    Pediatric Psychopharmacology Research Clinic, Massachusetts General Hospital, Boston, Massachusetts 02114, and New York University School of Medicine, New York, NY, USA
    Biol Psychiatry 61:1380-7. 2007
    ..This multicenter, randomized, fixed-dose, double-blind, placebo-controlled study evaluated efficacy of extended-release dexmethylphenidate (d-MPH-ER) in adults with attention-deficit/hyperactivity disorder (ADHD)...
  9. ncbi Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment
    Thomas J Spencer
    Massachusetts General Hospital Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    J Child Adolesc Psychopharmacol 17:689-700. 2007
    ..To examine the effects on growth of long-term pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), we present findings from an ongoing 5-year study of the efficacy and safety of treatment with atomoxetine...
  10. ncbi An open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension
    Timothy E Wilens
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston 02114, USA
    J Clin Psychiatry 67:696-702. 2006
    ....
  11. ncbi Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study
    Lenard A Adler
    New York University, School of Medicine, New York, NY 10016, USA
    J Atten Disord 12:248-53. 2008
    ..Previously, data from 97 weeks of open-label atomoxetine treatment of adults with attention-deficit/hyperactivity disorder (ADHD) were reported. This final report of that study presents results from over 4 years of treatment...
  12. ncbi The reliability and validity of self- and investigator ratings of ADHD in adults
    Lenard A Adler
    New York University School of Medicine, New York, NY 10016, USA
    J Atten Disord 11:711-9. 2008
    ....
  13. ncbi Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study
    Thomas J Spencer
    Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Ther 28:266-79. 2006
    ..The ability to recognize and diagnose attention-deficit/hyperactivity disorder (ADHD) has increased in recent years. The persistence of ADHD symptoms puts adolescents with ADHD at risk for long-term adverse psychosocial outcomes...
  14. ncbi A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects
    Joseph Biederman
    Clinical and Research Programs in Pediatric Psychiatry and Adult ADHD, Psychiatry Department, Massachusetts General Hospital, and Department of Psychiatry, Harvard Medical School, Boston, MA 02114, USA
    J Pediatr 157:635-40, 640.e1. 2010
    ..To assess the effect of attention-deficit/hyperactivity disorder (ADHD) and its treatment on growth outcomes in children followed into adulthood...
  15. ncbi Understanding the central pharmacokinetics of spheroidal oral drug absorption system (SODAS) dexmethylphenidate: a positron emission tomography study of dopamine transporter receptor occupancy measured with C-11 altropane
    Thomas J Spencer
    The Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 73:346-52. 2012
    ..However, there are no studies of central nervous system (CNS) dopamine transporter occupancies...
  16. ncbi Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane
    Thomas J Spencer
    Pediatric Psychopharmacology Unit, Psychiatry Service Massachusetts General Hospital, Boston, Massachusetts, USA
    Biol Psychiatry 62:1059-61. 2007
    ..The findings of in vivo neuroimaging of DAT in ADHD have been somewhat discrepant, however...
  17. ncbi Presenting ADHD symptoms, subtypes, and comorbid disorders in clinically referred adults with ADHD
    Timothy E Wilens
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, YAW 6A, 55 Fruit Street, Boston, MA 02114, USA
    J Clin Psychiatry 70:1557-62. 2009
    ..Comorbidity among adults with ADHD is also of great interest due to the high rates of psychiatric comorbidity, which can lead to a more persistent ADHD among adults...
  18. ncbi Novel treatments for attention-deficit/hyperactivity disorder in children
    Thomas J Spencer
    Pediatric Psychopharmacology Unit, Psychiatry Service, Massachusetts General Hospital, Boston, USA
    J Clin Psychiatry 63:16-22. 2002
    ....
  19. ncbi Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis
    Lenard A Adler
    New York University, New York, USA
    J Clin Psychiatry 66:294-9. 2005
    ..CONCLUSION: The results of this interim analysis of an ongoing, open-label study of adults with ADHD support the long-term efficacy, safety, and tolerability of atomoxetine for the treatment of adult ADHD...
  20. ncbi Preliminary examination of the reliability and concurrent validity of the attention-deficit/hyperactivity disorder self-report scale v1.1 symptom checklist to rate symptoms of attention-deficit/hyperactivity disorder in adolescents
    Lenard A Adler
    Department of Psychiatry, NYU School of Medicine, New York, NY 10016, USA
    J Child Adolesc Psychopharmacol 22:238-44. 2012
    ..To validate the attention-deficit/hyperactivity disorder (ADHD) Self-Report Scale (ASRS) v1.1 Symptom Checklist versus the clinician-administered ADHD Rating Scale (ADHD-RS) in adolescents with ADHD...
  21. ncbi Reliability and validity of the Time-Sensitive ADHD Symptom Scale in adults
    Lenard A Adler
    Department of Psychiatry, NYU School of Medicine, New York, NY 10010, USA
    Compr Psychiatry 52:769-73. 2011
    ..The objective of this study was to examine the psychometric properties of the Time-Sensitive ADHD Symptom Scale (TASS) to evaluate change of attention-deficit/hyperactivity disorder (ADHD) symptoms over the course of a day in adults...
  22. ncbi Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicent
    Thomas J Spencer
    Clinical and Research Program, Pediatric Psychopharmacology Research Unit, Massachusetts General Hospital and Harvard Medical School, Yawkey Center for Outpatient Care, Boston, Massachusetts 02114, USA
    Clin Ther 28:402-18. 2006
    ..Comorbid ODD is reportedly present in 40% to 70% of children and adolescents with attention-deficit/hyperactivity disorder (ADHD)...
  23. ncbi A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder
    Joseph Biederman
    Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Ther 28:280-93. 2006
    ....
  24. ncbi Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data
    Joseph Biederman
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital Harvard Medical School, Yawkey Center for Outpatient Care 6A, Boston, MA 02114, USA
    Psychopharmacology (Berl) 190:31-41. 2007
    ....
  25. ncbi Neural substrates of impaired sensorimotor timing in adult attention-deficit/hyperactivity disorder
    Eve M Valera
    Clinical and Research Programs in Pediatric Psychopharmacology and Adult Attention Deficit Hyperactivity Disorder, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Biol Psychiatry 68:359-67. 2010
    ..Also, the neural substrates of these deficits are largely unknown for both youth and adults with ADHD. The present study examined subsecond sensorimotor timing and its neural substrates in ADHD adults...
  26. ncbi Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD
    Joseph Biederman
    Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    CNS Spectr 10:16-25. 2005
    ..Assess the long-term safety and effectiveness of mixed amphetamine salts extended release (MAS XR) in adults with attention-deficit/hyperactivity disorder (ADHD) combined subtype...
  27. ncbi A positron emission tomography study examining the dopaminergic activity of armodafinil in adults using [¹¹C]altropane and [¹¹C]raclopride
    Thomas J Spencer
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Psychiatry 68:964-70. 2010
    ..With positron emission tomography imaging, we determined DAT occupancy and changes in extracellular dopamine by armodafinil in vivo...
  28. ncbi A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate
    Thomas J Spencer
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Atten Disord 15:286-94. 2011
    ..The main aim of this study was to examine the efficacy, tolerability, and compliance of an extended-release formulation of methylphenidate (OROS-MPH) in adults with ADHD receiving immediate-release methylphenidate (IR-MPH)...
  29. ncbi A PET study examining pharmacokinetics and dopamine transporter occupancy of two long-acting formulations of methylphenidate in adults
    Thomas J Spencer
    Pediatric Psychopharmacology Unit ACC 725, Massachusetts General Hospital, Boston, MA 02114, USA
    Int J Mol Med 25:261-5. 2010
    ..Moreover, a relatively small difference in plasma levels (1.4 ng/ml at 10 h) was associated with a more impressive difference in DAT occupancy ( approximately 10% at 10 h)...
  30. ncbi Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:253-9. 2005
    ..To evaluate the effects of medications used in the treatment of adults with attention-deficit/hyperactivity disorder (ADHD) on blood pressure and pulse...
  31. ncbi Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder
    Thomas J Spencer
    Clinical and Research Program, Pediatric Psychopharmacology, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, USA
    J Child Adolesc Psychopharmacol 19:501-10. 2009
    ....
  32. ncbi Representativeness of participants in a clinical trial for attention-deficit/hyperactivity disorder? Comparison with adults from a large observational study
    Craig B H Surman
    Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Ste 2000, 185 Alewife Brook Pkwy, Cambridge, MA 02138, USA
    J Clin Psychiatry 71:1612-6. 2010
    ..In particular, exclusion criteria may frequently exclude individuals with comorbid mental health conditions, which are common in the adult ADHD population...
  33. ncbi Toward defining deficient emotional self-regulation in children with attention-deficit/hyperactivity disorder using the Child Behavior Checklist: a controlled study
    Thomas J Spencer
    Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, MA 02114, USA
    Postgrad Med 123:50-9. 2011
    ..We examined whether a unique profile of the Child Behavior Checklist (CBCL) would help identify DESR in children with attention-deficit/hyperactivity disorder (ADHD)...
  34. ncbi An open trial of adjunctive donepezil in attention-deficit/hyperactivity disorder
    Timothy E Wilens
    Pediatric Psychopharmacology Unit, YAW 6A, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Child Adolesc Psychopharmacol 15:947-55. 2005
    ..We sought to determine if donepezil, used adjunctively to stimulant medication, would improve residual symptoms of ADHD and EF deficits...
  35. ncbi Psychiatric comorbidity and functioning in clinically referred preschool children and school-age youths with ADHD
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    J Am Acad Child Adolesc Psychiatry 41:262-8. 2002
    ..We evaluated the clinical characteristics, psychiatric comorbidity, and functioning of preschool children and school-age youths with ADHD referred to a pediatric psychiatric clinic for evaluation...
  36. ncbi New developments in the treatment of ADHD
    Joseph Biederman
    Dept. of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    J Clin Psychiatry 67:148-59. 2006
  37. ncbi Understanding attention-deficit/hyperactivity disorder from childhood to adulthood
    Timothy E Wilens
    Timothy E Wilens, MD, Pediatric Psychopharmacology Unit, YAW 6A, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA
    Postgrad Med 122:97-109. 2010
    ..Pharmacotherapy, including stimulants, noradrenergic agents, α-agonists, and antidepressants, plays a fundamental role in the long-term management of ADHD...
  38. ncbi Importance of pharmacokinetic profile and timing of coadministration of short- and long-acting formulations of methylphenidate on patterns of subjective responses and abuse potential
    Thomas J Spencer
    Massachusetts General Hospital, Boston, MA 02114, USA
    Postgrad Med 124:166-73. 2012
    ..Greater subjective responses have been documented in formulations that are more rapidly absorbed. However, repeat dosing has not been examined...
  39. ncbi Functional magnetic resonance imaging of methylphenidate and placebo in attention-deficit/hyperactivity disorder during the multi-source interference task
    George Bush
    Departments of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
    Arch Gen Psychiatry 65:102-14. 2008
    ..Stimulant medications are effective treatments for ADHD, but their neural effects have not been fully characterized...
  40. ncbi Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology
    Thomas J Spencer
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
    Ambul Pediatr 7:73-81. 2007
    ....
  41. ncbi Emotional dysregulation in adult ADHD and response to atomoxetine
    Frederick W Reimherr
    Mood Disorders Clinic, Department of Psychiatry, University of Utah Health Sciences Center, Salt Lake City, Utah 84132, USA
    Biol Psychiatry 58:125-31. 2005
    ....
  42. ncbi Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder
    Thomas J Spencer
    Massachusetts General Hospital, Boston, MA 02114, USA
    Pediatrics 116:e74-80. 2005
    ..This meta-analysis examined the effect on growth of atomoxetine, now approved in the United States for the treatment of attention-deficit/hyperactivity disorder...
  43. ncbi Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder
    Jeffrey H Newcorn
    Department of Psychiatry, Mount Sinai School of Medicine, New York 10029, USA
    J Am Acad Child Adolesc Psychiatry 44:240-8. 2005
    ..To examine (1) moderating effects of oppositional defiant disorder (ODD) on attention-deficit/hyperactivity disorder (ADHD) treatment response and (2) responses of ODD symptoms to atomoxetine...
  44. ncbi Overview and neurobiology of attention-deficit/hyperactivity disorder
    Thomas J Spencer
    Pediatric Psychopharmacology Unit, Psychiatry Service, Massachusetts General Hospital, Boston, USA
    J Clin Psychiatry 63:3-9. 2002
    ..Therefore, the treatment characteristics of newer, more selective treatments such as atomoxetine should continue to be explored in ADHD...
  45. ncbi Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder
    Joseph Biederman
    Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD at the Massachusetts General Hospital, Boston, MA 02114, USA
    BMC Psychiatry 7:49. 2007
    ..The main aim of this study was to compare the safety and efficacy of IR MPH administered three times daily to those of once daily OROS-MPH...
  46. ncbi Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome
    Thomas J Spencer
    Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA 02114 2696, USA
    J Atten Disord 11:470-81. 2008
    ..This study examines changes in severity of tics and ADHD during atomoxetine treatment in ADHD patients with Tourette syndrome (TS)...
  47. ncbi A randomized, placebo-controlled clinical trial of bupropion for the prevention of smoking in children and adolescents with attention-deficit/hyperactivity disorder
    Michael C Monuteaux
    Pediatric Psychopharmacology Program, Massachusetts General Hospital, USA
    J Clin Psychiatry 68:1094-101. 2007
    ....
  48. ncbi Stimulants and sudden death: what is a physician to do?
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Pediatrics 118:1215-9. 2006
    ..Recently, a US Food and Drug Administration advisory committee raised concerns about cardiovascular risks and sudden death in children and adolescents with attention-deficit/hyperactivity disorder who are receiving stimulants...
  49. ncbi Are stimulants effective in the treatment of executive function deficits? Results from a randomized double blind study of OROS-methylphenidate in adults with ADHD
    Joseph Biederman
    Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD at Massachusetts General Hospital, Boston, MA 02114, USA
    Eur Neuropsychopharmacol 21:508-15. 2011
    ..This randomized clinical trial showed that executive function deficits do not moderate the response to methylphenidate and measures of executive function deficits are not associated with response to OROS-MPH...
  50. ncbi New insights into the comorbidity between ADHD and major depression in adolescent and young adult females
    Joseph Biederman
    Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Am Acad Child Adolesc Psychiatry 47:426-34. 2008
    ..The main aim of this study was to evaluate the association between attention-deficit/hyperactivity disorder (ADHD) and major depression (MD) in adolescent and young adult females...
  51. ncbi Further understanding of the comorbidity between Attention-Deficit/Hyperactivity Disorder and bipolar disorder in adults: an MRI study of cortical thickness
    Nikos Makris
    Department of Psychiatry and Neurology, Harvard Medical School, Boston, MA, USA
    Psychiatry Res 202:1-11. 2012
    ..Attention to comorbidity is necessary to help clarify the heterogeneous neuroanatomy of both BPD and ADHD...
  52. ncbi Functional outcomes in the treatment of adults with ADHD
    Lenard A Adler
    Department of Psychiatry, New York University School of Medicine, New York, NY 10010, USA
    J Atten Disord 11:720-7. 2008
    ..ADHD is associated with significant functional impairment in adults. The present study examined functional outcomes following 6-month double-blind treatment with either atomoxetine or placebo...
  53. ncbi Issues in the management of patients with complex attention-deficit hyperactivity disorder symptoms
    Thomas J Spencer
    Harvard Medical School, Clinical and Research Program, Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    CNS Drugs 23:9-20. 2009
    ..Nevertheless, identification and appropriate treatment must be given a high priority for these highly vulnerable patients to derive optimal benefits from treatment...
  54. ncbi Plasma and brain concentrations of oral therapeutic doses of methylphenidate and their impact on brain monoamine content in mice
    Aygul Balcioglu
    Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Neuropharmacology 57:687-93. 2009
    ....
  55. ncbi Cerebellar vermis involvement in cocaine-related behaviors
    Carl M Anderson
    Brain Imaging Center, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USA
    Neuropsychopharmacology 31:1318-26. 2006
    ....
  56. ncbi Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series
    Robert L Doyle
    Department of Psychiatry, Harvard Medical School, USA
    J Atten Disord 9:543-9. 2006
    ..Because work in dementia documents improvement in executive function deficits with the acetylcholinesterase inhibitor donepezil, the authors reason that similar benefits could be obtained in PDD...
  57. ncbi ADHD treatment across the life cycle
    Thomas J Spencer
    Department of Pediatric Psychopharmacology, Massachusetts General Hospital, Department of Psychiatry, Harvard Medical School, Boston 02114, USA
    J Clin Psychiatry 65:22-6. 2004
    ..This article reviews the use of long-acting methylphenidate, mixed amphetamine salts, desipramine, monoamine oxidase inhibitors, bupropion, and atomoxetine in studies of children, adolescents, and adults with ADHD...
  58. ncbi Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro
    Bertha K Madras
    Department of Psychiatry, Harvard Medical School, New England Primate Research Center, 1 Pine Hill Dr, Southborough, MA 01772 9102, USA
    J Pharmacol Exp Ther 319:561-9. 2006
    ..The present data provide compelling evidence that modafinil occupies the DAT and NET in living brain of rhesus monkeys and raise the possibility that modafinil affects wakefulness by interacting with catecholamine transporters in brain...
  59. ncbi Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community
    Joseph Biederman
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Yawkey Center for Outpatient Care, Boston, MA 02114, USA
    J Clin Psychiatry 67:524-40. 2006
    ..The objective of this study was to evaluate functional impairments in a nonreferred sample of adults identifying themselves as having been diagnosed with attention-deficit/hyperactivity disorder (ADHD) by a clinician in their community...
  60. ncbi ADHD and comorbidity in childhood
    Thomas J Spencer
    Pediatric Psychopharmacology Unit, Psychiatry Service, Massachusetts General Hospital, and the Department of Psychiatry, Harvard Medical School, Boston, Mass 02114, USA
    J Clin Psychiatry 67:27-31. 2006
    ..Investigation of these issues should help to clarify the etiology, course, and outcome of ADHD...
  61. ncbi Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology
    Thomas J Spencer
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    J Pediatr Psychol 32:631-42. 2007
    ....
  62. ncbi Pharmacology of adult ADHD with stimulants
    Thomas J Spencer
    Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, Massachusetts, USA
    CNS Spectr 12:8-11. 2007
  63. ncbi A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors
    Timothy E Wilens
    Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    J Child Adolesc Psychopharmacol 13:143-52. 2003
    ..To this end we completed a retrospective analysis of medical charts to determine the incidence, nature, and clinical correlates of treatment emergent adverse effects in the behavioral, cognitive, and emotional domains...
  64. ncbi Preliminary reliability and validity of a new time-sensitive ADHD symptom scale in adolescents with ADHD
    Lenard A Adler
    Department of Psychiatry, NYU School of Medicine and Psychiatry Service, NY VA Harbor Healthcare System, New York, NY 10016, USA
    Postgrad Med 123:7-13. 2011
    ..To validate the Time-Sensitive ADHD Symptom Scale (TASS) in the assessment of symptom change during the day in adolescents with attention-deficit/hyperactivity disorder (ADHD)...
  65. ncbi A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder
    Timothy E Wilens
    Massachusetts General Hospital, Boston, MA 02114, USA
    J Atten Disord 5:189-202. 2002
    ..Despite the increasing recognition of attention deficit hyperactivity disorder (ADHD) in adults, the use of pharmacotherapeutics remains less established...
  66. ncbi Psychopharmacological interventions
    Joseph Biederman
    Pediatric Psychopharmacology Research Unit, Massachusetts General Hospital, 32 Fruit Street, YAW 6A, Boston, MA 02114, USA
    Child Adolesc Psychiatr Clin N Am 17:439-58, xi. 2008
    ..Cognitive and cognitive/behaviorally based psychotherapies combined with medication may play a role in treating behavioral and organizational issues and comorbid psychopathology...
  67. ncbi Patterns of psychopathology and dysfunction in clinically referred preschoolers
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    J Dev Behav Pediatr 23:S31-6. 2002
    ..Preschoolers referred for psychiatric services had high rates of psychopathology with prominent comorbidity and associated dysfunction. These preschoolers are likely to require aggressive interventions including psychopharmacology...
  68. ncbi A family study of the high-risk children of opioid- and alcohol-dependent parents
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Boston 02114, USA
    Am J Addict 11:41-51. 2002
    ..With a growing consensus that certain risk factors for later SUD start in childhood with potentially treatable childhood-onset disorders, new preventive approaches for individuals at risk may be developed targeting childhood precursors of..
  69. ncbi Attention-deficit/hyperactivity disorder in adults: a survey of current practice in psychiatry and primary care
    Stephen V Faraone
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Arch Intern Med 164:1221-6. 2004
    ..Recognition and treatment of attention-deficit/hyperactivity disorder (ADHD) in adults in psychiatry and primary care have faced many obstacles...
  70. ncbi Attention-deficit/hyperactivity disorder in children and adolescents with obsessive-compulsive disorder: fact or artifact?
    Daniel A Geller
    Obsessive Compulsive Disorder Clinic, McLean Hospital, Belmont, MA 02478, USA
    J Am Acad Child Adolesc Psychiatry 41:52-8. 2002
    ....
  71. ncbi Attention deficit/hyperactivity disorder across the lifespan
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, 15 Parkman Street, Boston, Massachusetts 02114, USA
    Annu Rev Med 53:113-31. 2002
    ..Pharmacotherapy, including stimulants, antidepressants, and antihypertensives, plays a fundamental role in the management of ADHD across the lifespan...
  72. ncbi The epidemiology of adult ADHD
    Thomas J Spencer
    Harvard Medical School, Boston, MA, USA
    CNS Spectr 13:6-8. 2008
  73. ncbi Treatment of adult ADHD and comorbid depression
    Thomas J Spencer
    Harvard Medical School, Boston, Massachusetts, USA
    CNS Spectr 13:14-6. 2008
  74. ncbi Patterns of comorbidity and dysfunction in clinically referred preschool and school-age children with bipolar disorder
    Timothy E Wilens
    Johnson and Johnson Center for the Study of Pediatric Psychopathology, Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    J Child Adolesc Psychopharmacol 13:495-505. 2003
    ..This study reports on the clinical characteristics, psychiatric comorbidity, and functioning of preschoolers identified with BPD who were referred to a pediatric psychiatric clinic...
  75. ncbi Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children
    Robert L Findling
    University Hospitals of Cleveland, Cleveland, Ohio 44106 5080, USA
    J Pediatr 147:348-54. 2005
    ....
  76. ncbi Comparing the efficacy of medications for ADHD using meta-analysis
    Stephen V Faraone
    Professor of Psychiatry Director, Child and Adolescent Psychiatry Research, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, New York Email
    MedGenMed 8:4. 2006
    ..Medications used to treat attention-deficit/hyperactivity disorder (ADHD) have been well researched, but comparisons among drugs are hindered by the absence of direct comparative trials...
  77. ncbi A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year
    Jan K Buitelaar
    University Medical Center St Radboud, Nijmegen, The Netherlands
    Biol Psychiatry 61:694-9. 2007
    ..The efficacy of atomoxetine in maintaining symptom response following 1 year of treatment was assessed in children and adolescents (n = 163) with DSM-IV defined attention-deficit/hyperactivity disorder (ADHD)...
  78. ncbi Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial
    Christopher J Kratochvil
    University of Nebraska Medical Center, USA
    J Am Acad Child Adolesc Psychiatry 41:776-84. 2002
    ..4%) for atomoxetine and 5/44 (11.4%) for methylphenidate; p = .175. CONCLUSION: These data provide preliminary evidence that atomoxetine is associated with therapeutic effects comparable to those of methylphenidate...
  79. ncbi Adaptive changes related to medication treatment of ADHD: listening to parents of children in clinical trials of a novel nonstimulant medication
    Keith E Saylor
    Neuroscience, Inc, Old Georgetown Road Manor House, 5612 Spruce Tree Ave, 3rd Floor, Bethesda, MD 20814, USA
    J Clin Psychiatry 63:23-8. 2002
    ..Research protocols that omit parental interviews that assess adaptive and executive function may well overlook several meaningful and consequential medication-related improvements...
  80. ncbi Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD
    James T McCracken
    Department of Psychiatry and Biobehavioral Sciences, Division of Child andAdolescent Psychiatry, UCLA Neuropsychiatric Institute, Los Angeles, CA 90024 1759, USA
    J Am Acad Child Adolesc Psychiatry 42:673-83. 2003
    ..Secondary objectives included examination of the time course, pharmacokinetic, and pharmacodynamic properties of SLI381...
  81. ncbi Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall
    James J McGough
    Department of Psychiatry and Biobehavioral Sciences, Division of Child and Adolescent Psychiatry, UCLA Neuropsychiatric Institute, Los Angeles, USA
    J Am Acad Child Adolesc Psychiatry 42:684-91. 2003
    ..To assess the pharmacokinetic (PK) properties of a single daily dose of Adderall (mixed amphetamine salts) and the extended-release formulation, SLI381 (ADDERALL XR), in pediatric attention-deficit/hyperactivity disorder (ADHD)...
  82. ncbi Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial
    Richard H Weisler
    University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    CNS Spectr 11:625-39. 2006
    ..Functional impairments, underachievement, and difficult interpersonal relationships illustrate the need for effective treatment of ADHD through adulthood...
  83. ncbi Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children
    Joseph Biederman
    Scientific Communications, Lilly Research Laboratories, Indianapolis, Indiana, USA
    Biol Psychiatry 60:1106-10. 2006
    ..This study assessed whether parent reports were as sensitive as teacher reports to document change in ADHD symptoms during clinical trials with atomoxetine...
  84. ncbi A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder
    Sharon B Wigal
    Child Development Center, University of California, Irvine, CA 92612, USA
    J Atten Disord 9:275-89. 2005
    ..001). Adverse events were similar for both treatment groups. The extended time course of action and greater therapeutic efficacy of MAS XR suggests that it is more effective than atomoxetine in children with ADHD...
  85. ncbi Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study
    David Michelson
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    J Am Acad Child Adolesc Psychiatry 43:896-904. 2004
    ..Attention-deficit/hyperactivity disorder (ADHD) is typically treated over extended periods; however, few placebo-controlled, long-term studies of efficacy have been reported...
  86. ncbi Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD
    Richard H Weisler
    Duke University Medical Center, University of North Carilina, Chapel Hill, Raleigh 27609, USA
    CNS Spectr 10:35-43. 2005
    ..To assess long-term cardiovascular effects of mixed amphetamine salts extended release (MAS XR) in adults with attention-deficit/hyperactivity disorder (ADHD) combined subtype...
  87. ncbi Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression
    Mark E Bangs
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    J Child Adolesc Psychopharmacol 17:407-20. 2007
    ..ATX was an effective and safe treatment for ADHD in adolescents with ADHD and MDD. However, this trial showed no evidence for ATX of efficacy in treating MDD...

Research Grants6

  1. CONTROLLED STUDY OF METHYLPHENIDATE IN ADULTS WITH ADHD
    Thomas Spencer; Fiscal Year: 2002
    ..The auditory and visual continuous performance tasks and the Stroop test will be used to further assess treatment efficacy. A larger neuropsychological battery will be used to assess the long term effects of MPH treatment. ..
  2. Dopamine Transporter Binding by PET in Adult ADHD
    Thomas Spencer; Fiscal Year: 2007
    ..qenetic risk factors, a) We hypothesize that DAT binding will be associated with the 480 allele of the 40-bp VNTR in the 3'-untranslated region of the dopamine transporter gene. ..